Loading clinical trials...

Multiple Firings in Double-stapled Colorectal Anastomosis | Clinical Trials | Clareo Health

COMPLETED

Multiple Firings in Double-stapled Colorectal Anastomosis

Risk Factors for the Usage of ≥3 Linear Stapler Cartridges During Double Stapling Anastomosis in Laparoscopic Low Anterior Resection of Rectal Cancer

NCT05498506•Shanghai Minimally Invasive Surgery Center

View on ClinicalTrials.gov

Summary

Multiple linear stapler firings during double stapling technique (DST) is associated with anastomotic leakage (AL) after laparoscopic low anterior resection (LAR). We aim to investigate the risk factors and then to develop a deep learning model to predict the usage of ≥3 linear stapler cartridges during DST anastomosis.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1\) carcinoma of rectum confirmed by histopathological evaluation;
•2\) tumor located in the mid-low rectum (less than 10cm from the anal verge);
•3\) performance of DST anastomosis;
•4\) pelvic MRI obtained within 14 days before surgery.

Exclusion Criteria

•1\) other anastomotic techniques (e.g., trans-anal rectal excision);
•2\) Hartmann's operation or other procedures without anastomosis;
•3\) the number of linear stapler cartridges was not traceable in the operative report.

Locations (1)

Ruijin Hospital

Shanghai, China

Key Dates

Start Date

December 1, 2022

Primary Completion Date

December 31, 2022

Completion Date

January 31, 2023

Last Updated

February 26, 2024

Enrollment

350

ACTUAL participants

Conditions

Rectal Cancer

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

NCT04929028

View study

RECRUITINGPHASE1

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

NCT04704661

Advanced Breast CarcinomaAdvanced Colon Carcinoma+38 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 26, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Multiple Firings in Double-stapled Colorectal Anastomosis

Inclusion Criteria

Exclusion Criteria

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Resilience and Equity in Aging, Cancer, and Health (REACH)